Pregabalin Capsule
Product Images NDC 80425-0124

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin dosed at 200 mg, 150 mg, and 25 mg three times a day compared with placebo. The graph shows trends of patient improvement across varying levels of pain relief.*

FDA Label Image

Fig 10

A Kaplan-Meier survival curve chart depicting the estimated percentage of subjects without LTR (lasting treatment response) over a period of 180 days, comparing Pregabalin and Placebo groups. The x-axis represents days, and the y-axis represents the estimated percent of subjects without LTR, showing separate lines for Pregabalin and Placebo.*

FDA Label Image

Fig 11

A line graph showing percent of subjects improved over time from baseline to week 12. The x-axis represents percent improvement, and the y-axis shows the percent of subjects improved. Two lines compare Pregabalin and Placebo treatments, with Pregabalin generally showing higher improvement percentages than Placebo.*

FDA Label Image

Fig 12

A line graph depicting the percent of subjects improved over time, comparing Pregabalin and placebo. The x-axis shows percent improvement from baseline to week 16 BOCF, and the y-axis shows percent of subjects improved. Two lines represent Pregabalin (solid) and placebo (dashed), illustrating higher improvement rates for Pregabalin.*

FDA Label Image

Fig 2

A line graph depicting percent improvement in pain from baseline versus percent of patients improved. Two lines compare Pregabalin 100 mg three times a day and placebo groups, showing that the Pregabalin group generally has a higher percentage of patients with pain improvement across various thresholds.*

FDA Label Image

Fig 3

A line graph displaying the percent of patients improved against percent improvement in pain from baseline. The graph compares Pregabalin at dosages of 75 mg, 150 mg, and 300 mg taken twice a day versus placebo, showing trends over increasing pain improvement percentages.*

FDA Label Image

Fig 4

This chart presents the percent of patients improved versus the percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo group. The chart uses lines to show patient improvement rates across different pain improvement percentages.*

FDA Label Image

Fig 5

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating differences in pain improvement among these groups.*

FDA Label Image

Fig 6

A bar chart comparing responder rates (%) across two studies, Study E1 and Study E3, for different dose levels of pregabalin and placebo. The chart shows increasing responder rates with higher pregabalin doses, including 50, 150, 300, 600 mg/day in Study E1 and 600 mg/day in Study E3 with BID and TID dosing. Sample sizes are indicated below each bar, with a note on statistically significant differences versus placebo.*

FDA Label Image

Fig 7

A line graph depicting seizure reduction as the median percentage change from baseline versus dose in mg/day for Pregabalin capsules. The chart compares four studies (E1 BID, E2 TID, E3 BID, and E3 TID) with doses including placebo (0 mg), 50 mg, 150 mg, 300 mg, and 600 mg. Significant p-values are noted, showing increasing seizure reduction with higher doses.*

FDA Label Image

Fig 9

A line graph depicting the percent of patients improved against percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, 600 mg, and placebo. The graph shows trends of patient improvement across different pain improvement percentages for each treatment group.*

FDA Label Image

Formula

A formula for calculating creatinine clearance (CLCr), showing the equation using age, weight, serum creatinine levels, and a multiplication factor of 0.85 for female patients. This panel provides information relevant to dosing considerations.*

FDA Label Image

Pregabalin 150mg Cap Qty 90 80425 0124

Label for Pregabalin 150 mg capsules, packaged by Advanced Rx Pharmacy of Tennessee, LLC in Nashville, TN. The label includes the product NDC 80425-0124-03, lot number PG150622, and source NDC 69238-1314-09. It provides storage instructions at 20°-25°C (68°-77°F) and includes a barcode along with a caution stating federal restrictions on drug transfer.*

FDA Label Image

Structure

Chemical structure of pregabalin, showing the molecular arrangement of its atoms and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.